Mucoadhesive polymers in peroral peptide drug delivery. V. Effect of poly(acrylates) on the enzymatic degradation of peptide drugs by intestinal brush border membrane vesicles

International Journal of Pharmaceutics

Volumn 141, Issue 1-2, 1996, Pages 39-52

  Luessen H L ^a   Bohner, V ^b   Perard D ^a   Langguth, P ^b   Verhoef, J C ^a   De Boer, A G ^a   Merkle, H P ^b   Junginger, H E ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ETH ZURICH   (Switzerland)

Author keywords

9 Desglycinamide, 8 arginine vasopressin (DGAVP); Brush border membrane vesicles; Buserelin; Carbomer; Enzyme inhibition; Insulin; Metkephamid; Peroral peptide drug delivery; Polycarbophil

Indexed keywords

ARGIPRESSIN[DEGLYCINAMIDE]; BUSERELIN ACETATE; CARBOMER; CARBOPOL 934; INSULIN; METKEPHAMID; NOVEON; POLYCARBOPHIL; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; INTESTINE BRUSH BORDER MEMBRANE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0030572687     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(96)04613-3     Document Type: Article

References (33)

1. Akiyama, Y., Lueßen, H.L., de Boer, A.G., Verhoef, J.C. and Junginger, H.E., Novel peroral dosage forms with protease inhibitory activities. I. Design of capsules with fast gel-forming and fast drug-releasing properties. Int. J. Pharm., 136 (1996a) 155-163.
2. Akiyama, Y., Lueßen, H.L., de Boer, A.G., Verhoef, J.C. and Junginger, H.E., Novel peroral dosage forms with protease inhibitory activities. II. Design of fast dissolving poly(acrylate) and controlled drug-releasing capsule formulations with trypsin inhibiting properties. Int. J. Pharm., (1996a) in press.
3. Armentrout, R.W. and Doolittle, R.F., Pyrrolidonecarboxyl peptidase: stabilization and purification. Arch. Biochem. Biophys., 132 (1969) 80-90.
4. Biber, J., Stieger, B., Haase, W. and Murer, H., A high yield preparation for rat kidney brush border membranes - different behaviour of lysosomal markers. Biochim. Biophys. Acta, 647 (1981) 169-176.
5. Bohley, P. and Seglen, P.O., Proteases and proteolysis in the lysosome. Experientia, 48 (1992) 151-157.
6. 8)-vasopressin on memory in healthy subjects. Neuropsychobiology, 23 (1990) 82-88.
7. Chan, W.W.-C. and Pfuetzner, R.A., General occurence of binding synergism in zinc proteases and its possible significance. Eur. J. Biochem., 218 (1993) 529-534.
8. Cleland, J.L., Powell, M.F. and Shire, S.J., The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Therapeutic Drug Carrier Syst., 10 (1993) 307-377.
9. Constantinides, P.P., Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res., 12 (1995) 1561-1572.
10. Guasch, A., Coll, M., Avilés, F.X. and Huber, R., Three-dimensional structure of porcine pancreatic procarboxypeptidase A - a comparison of the A and B zymogens and their determinants for inhibition and activation. J. Mol. Biol., 224 (1992) 141-157.
11. Hasilik, A., The early and late processing of lysosomal enzymes: proteolysis and compartimentation. Experientia, 48 (1992) 130-150.
12. Hofland, H.E.J., Bouwstra, J.A., Spies, F., Talsma, H. and Junginger, H.E., Non-ionic surfactant vesicles: a study of vesicle formation, characterization, and stability. J. Colloid Interface Sci., 161 (1993) 366-376. *
13. Langguth, P., Bohner, V., Biber, J. and Merkle, H.P., Metabolism and transport of the pentapeptide by brush-border membrane vesicles of rat intestine. J. Pharm. Pharmacol., 46 (1994a) 34-40.
14. Langguth, P., Merkle, H.P. and Amidon, G.L., Oral absorption of peptides: the effect of absorption site and enzyme inhibition on the systemic availability of metkephamid. Pharm. Res., 11 (1994b) 528-535.
15. Lee, V.H.L., Traver, R.D. and Taub, M.E., Enzymatic barriers to peptide and protein drug delivery. In Lee, V.H.L. (Ed.), Peptide and Protein Drug Delivery, Marcel Dekker, New York, 1991, pp. 303-358.
16. Lowe, P.J. and Temple, C.S., Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol., 46 (1994) 547-552.
17. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J., Protein measurement with the folin phenol reagent. J. Biol. Chem., 193 (1951) 265-275.
18. Lueßen, H.L., Borchard, G., Verhoef, J.C., Lehr, C.-M., de Boer, A.G. and Junginger, H.E., Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm. Res., 12 (1995) 1293-1298.
19. Lueßen, H.L., de Leeuw, B.J., Pérard, D., Lehr, C.-M., de Boer, A.G., Verhoef, J.C. and Junginger, H.E., Mucoadhesive excipients in peroral peptide drug delivery. I. Influence of mucoadhesive excipients on the proteolytic activity of intestinal enzymes. Eur. J. Pharm. Sci., 4 (1996) 117-128.
20. Lueßen, H.L., Lehr C.-M., Rentel, C.-O., Noach, A.B.J., de Boer, A.G., Verhoef, J.C. and Junginger, H.E., Bioadhesive polymers for the peroral delivery of peptide drugs. J. Controlled Rel., 29 (1994) 329-338.
21. Lueßen, H.L., Rentel, C.-O., Kotzé, A., Lehr, C.-M., de Boer, A.G., Verhoef, J.C. and Junginger, H.E., Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. J. Controlled Rel., (in press).
22. Matthes, I., Nimmerfall, F. and Sucker, H., Mucus models for investigation of intestinal absorption. Part 2: Mechanisms of drug interaction with intestinal mucus. Pharmazie, 47 (1992) 609-613.
23. Morishita, I., Morishita, M., Takayama, K., Machida, Y. and Nagai, T., Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int. J. Pharm., 78 (1992) 9-16.
24. Rubinstein, A., Tirosh, B., Baluom, M., Nassar, T., David, A., Radai, R., Gliko-Kabir, I. and Friedmann, M., The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools. J. Controlled Rel., (1996) in press.
25. Saffran, M., Breda, C., Kumar, G.S. and Neckers, D.C., Vasopressin: a model for the study of effects of additives on the oral and rectal administration of peptide drugs. J. Pharm. Sci., 77 (1988) 33-38.
26. Sandow, J., Physiologische und pharmakologische Wirkungen von Buserelin: präklinische Untersuchungen. In Schindler, A.E. and Schweppe K.W. (Eds.), Endometriose-Neue Therapiemöglichkeiten durch Buserelin. Walter de Gryter, Berlin, 1989, pp. 23-42.
27. Schilling, R.J. and Mitra, A., Degradation of insulin by trypsin and α-chymotrypsin. Pharm. Res., 8 (1991) 721-727.
28. Seglen, P.O. and Bohley, P., Autophagy and other vacuolar protein degradation mechanisms. Experientia, 48 (1992) 158-171.
29. Strous, G.J. and Dekker, J., Mucin-type glycoproteins. Crit. Rev. Biochem. Mol., 27 (1992) 57-92.
30. Szewczuk, A. and Mulczyk, M., Pyrrolidonyl peptidase in bacteria. The enzyme from Bacillus subtillis. Eur. J. Biochem., 8 (1969) 63-67.
31. Ter Braak, E.W.T.M., Bianci, R. and Erkelens, D.W., Faster, shorter and more profound action of Lys (B28) Pro (B29) human insulin analogue compared to regular insulin irrespective of the injection site. Diabetes, 42 (1993) 207A.
32. 3H]9-desglycinamide, 8-arginine vasopressin: metabolism and in-vivo fate. J. Endocrinol., 110 (1986) 557-562.
33. Zhou, X.H., Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J. Controlled Rel., 29 (1994) 239-252.